WordNet

street name for lysergic acid diethylamide (同)back breaker, battery-acid, dose, dot, Elvis, loony toons, Lucy in the sky with diamonds, pane, superman, window pane, Zen
any of various water-soluble compounds having a sour taste and capable of turning litmus red and reacting with a base to form a salt
having the characteristics of an acid; "an acid reaction"

PrepTutorEJDIC

酸性の / 酸味のある,すっぱい(sour) / (言葉・態度などが)厳しい,しんらつな / 酸 / すっぱいもの / 《俗》=LSD

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/07/16 12:48:37」(JST)

wiki en

[Wiki en表示]

Risedronic acid (INN) often used as its sodium salt risedronate sodium (USAN) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.

Administration

Risedronate is taken orally, usually weekly or monthly. Notably, if risedronate lodges in the esophagus, it can lead to esophageal ulcers. Therefore, it is recommended that risedronate be taken with the body upright, and followed by a glass of water. Moreover, risedronate is poorly absorbed when taken with food, so it is recommended that no food or drink other than water be taken for 2 hours before and 30 minutes after taking risedronate. Risedronate has a faster esophageal transit time and different chemical chain which results in less gastrointestinal side-effects than other drugs in this class. The dosage instructions also show that risedronate can be taken with less water than other drugs in the class. Risedronate is also available as a 75 mg tablet to be taken on two consecutive days each month (2CDM) in order to optimize patient adherence. This formulation has been studied in a randomized, double-blind, parallel-group, multinational trial in 1229 postmenopausal women with osteoporosis.^[1]

Controversies

In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.^[2] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".^[3]

In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports^[4] and discussion).^[5]

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.

References

^ Frampton JE. Risedronate on Two Consecutive Days per Month : Drugs & Aging. Drugs&Aging 2009; 26(4):355-362. doi:10.2165/00002512-200926040-00006.
^ "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.
^ NY fed judge finds promotions for bone drug Boniva are fair Associated Press, 7 Sept 2006^{[dead link]}
^ http://www.thejabberwock.org/wiki/index.php?title=Actonel_Case_Media_Reports
^ "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.

External links

Actonel adverse events reported to the FDA
Risedronic acid bound to proteins in the PDB

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 閉経後女性における骨粗鬆症に対するビスホスホネート投与 the use of bisphosphonates in postmenopausal women with osteoporosis
2. 骨粗鬆症患者におけるビスホスホネート療法のリスク risks of bisphosphonate therapy in patients with osteoporosis
3. ビスホスホネートの薬理学 pharmacology of bisphosphonates
4. ステロイド誘発性骨粗鬆症の予防および治療 prevention and treatment of glucocorticoid induced osteoporosis
5. 骨パジェット病の治療 treatment of paget disease of bone

English Journal

Production, quality control, and determination of human absorbed dose of no carrier added 177 Lu-risedronate for bone pain palliation therapy.

Salek N1,2, Mehrabi M2, Shirvani Arani S1, Bahrami Samani A1, Erfani M1, Vosoghi S1, Ghannadi Maragheh M1, Shamsaei M2.
Journal of labelled compounds & radiopharmaceuticals.J Labelled Comp Radiopharm.2016 Nov 15. doi: 10.1002/jlcr.3466. [Epub ahead of print]
In this study, the radiocomplexation of risedronic acid, a potent bisphosphonate with a no carrier added (NCA) 177 Lu, was investigated and followed by quality control studies, biodistribution evaluation, and dosimetry study for human based on biodistribution data in Wistar rats. The moderate energy
PMID 27862203

Polymer-ceramic Monolithic In-Needle Extraction (MINE) device: Preparation and examination of drug affinity.

Pietrzyńska M1, Tomczak R2, Jezierska K2, Voelkel A2, Jampílek J3.
Materials science & engineering. C, Materials for biological applications.Mater Sci Eng C Mater Biol Appl.2016 Nov 1;68:70-7. doi: 10.1016/j.msec.2016.05.097. Epub 2016 May 24.
Polymer-ceramic materials were placed in the in-needle device. Polymer-ceramic Monolithic In-Needle Extraction (MINE) device is an extraction device used in sample preparation step but, on the other hand, it can be a tool for examination of interactions between potential antiresorptive drugs and bon
PMID 27523998

Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.

Belhassen M1,2,3, Confavreux CB4, Cortet B5, Lamezec L6, Ginoux M7,8, Van Ganse E7,8,9.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.Osteoporos Int.2016 Oct 20. [Epub ahead of print]
Limited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006-2013, the most frequently prescribed first-line treatment class for osteoporosis was represented by bisphosphonates (alendronic acid and risedronic acid), followed by strontium ranelate. Persistenc
PMID 27766368

Japanese Journal

閉経後骨粗鬆症に対する塩酸ラロキシフェンの骨代謝マーカーに対する変化--年齢を一致させたリセドロネート投与患者との短期の比較検討 (CONTRIBUTION 骨粗鬆症の診断と治療)

田賀谷健一,山口良兼
オステオポローシスジャパン 14(2), 381-385, 2006-00-00
NAID 40007315217

「リセドロン酸」

Risedronic acid
Systematic (IUPAC) name
	(1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: B3; US: C (Risk not ruled out); ;
Routes of; administration	Oral
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	0.63%
Protein binding	~24%
Metabolism	None
Biological half-life	1.5 h
Excretion	Renal and fecal
Identifiers
CAS Number	105462-24-6
ATC code	M05BA07 (WHO)
PubChem	CID 5245
IUPHAR/BPS	3176
DrugBank	DB00884
ChemSpider	5055
UNII	KM2Z91756Z
ChEMBL	CHEMBL923
Chemical data
Formula	C7H11NO7P2
Molar mass	283.112 g/mol
	SMILES OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O ;
	InChI InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15) ; Key:IIDJRNMFWXDHID-UHFFFAOYSA-N ;
(what is this?) (verify)